Department of Immunology, Institute of Microbiology, Bulgarian Academy of Sciences and Enzolytics, Inc. Execute Three Year Agreement
Enzolytics, Inc. (OTC PINK:ENZC) has entered a three-year agreement with the Department of Immunology, Institute of Microbiology, Bulgarian Academy of Sciences. The collaboration aims to accelerate the discovery of combined applications and commercialization of their technologies, focusing initially on combining Monoclonal Antibodies and Immune Therapeutic Proteins (ITP) for treating malignant antigens.
The agreement involves conducting future investigations, including pharmacokinetics, pre-clinical, and clinical trials. This partnership leverages the expertise of the Stephan Angeloff Institute of Microbiology (SAIM), which boasts a scientific staff of 82 and over 30 ongoing research projects funded by various international institutions.
Additionally, a recent study conducted at the Ministry of Health National Centre of Infectious and Parasitic Diseases in Sofia, Bulgaria, concluded that ENZC's patented experimental cancer lyophilized pepsin treatment is effective in decreasing the growth and spread of various cancer types, including breast, colon, prostate, larynx, and small cell lung cancer.
Enzolytics, Inc. (OTC PINK:ENZC) ha stipulato un accordo triennale con il Dipartimento di Immunologia, Istituto di Microbiologia, Accademia Bulgara delle Scienze. La collaborazione si propone di accelerare la scoperta di applicazioni combinate e la commercializzazione delle loro tecnologie, concentrandosi inizialmente sulla combinazione di Anticorpi Monoclonali e Proteine Terapeutiche Immunologiche (ITP) per il trattamento degli antigeni maligni.
L'accordo prevede di condurre future indagini, incluse le farmacocinetiche, studi preclinici e clinici. Questa partnership sfrutta l'expertise dell'Istituto di Microbiologia Stephan Angeloff (SAIM), che vanta un personale scientifico di 82 unità e oltre 30 progetti di ricerca in corso finanziati da diverse istituzioni internazionali.
Inoltre, uno studio recente condotto presso il Centro Nazionale di Malattie Infettive e Parassitarie del Ministero della Salute a Sofia, Bulgaria, ha concluso che il trattamento sperimentale brevettato di pepsina liofilizzata di ENZC è efficace nel ridurre la crescita e la diffusione di vari tipi di cancro, inclusi quelli alla mammella, al colon, alla prostata, alla laringe e al polmone a piccole cellule.
Enzolytics, Inc. (OTC PINK:ENZC) ha celebrado un acuerdo de tres años con el Departamento de Inmunología, Instituto de Microbiología, Academia Búlgara de Ciencias. La colaboración tiene como objetivo acelerar el descubrimiento de aplicaciones combinadas y la comercialización de sus tecnologías, enfocándose inicialmente en combinar Anticuerpos Monoclonales y Proteínas Terapéuticas Inmunológicas (ITP) para tratar antígenos malignos.
El acuerdo incluye la realización de futuras investigaciones, incluidas farmacocinéticas, ensayos preclínicos y clínicos. Esta asociación aprovecha la experiencia del Instituto de Microbiología Stephan Angeloff (SAIM), que cuenta con un personal científico de 82 y más de 30 proyectos de investigación en curso financiados por diversas instituciones internacionales.
Además, un estudio reciente realizado en el Centro Nacional de Enfermedades Infecciosas y Parasitarias del Ministerio de Salud en Sofía, Bulgaria, concluyó que el tratamiento experimental patentado de pepsina liofilizada de ENZC es efectivo para disminuir el crecimiento y la diseminación de varios tipos de cáncer, incluidos el de mama, colon, próstata, laringe y pulmón de células pequeñas.
Enzolytics, Inc. (OTC PINK:ENZC)는 불가리아 과학 아카데미 미생물학 연구소 면역학과와 3년 계약을 체결했습니다. 이 협력은 초기 단계에서 단클론 항체와 면역 치료 단백질 (ITP)의 조합을 통해 악성 항원을 치료하기 위한 기술의 발견 및 상용화를 가속화하는 것을 목표로 합니다.
계약은 약리학, 전임상 및 임상 시험을 포함한 미래 조사 수행을 포함합니다. 이 파트너십은 82명의 과학 인력을 보유하고 30개 이상의 국제 기관에서 자금을 지원받는 연구 프로젝트를 진행하는 스테판 안젤로프 미생물학 연구소(SAIM)의 전문성을 활용합니다.
또한, 불가리아 소피아에 있는 보건부 감염병 및 기생충 질병 국가 센터에서 수행된 최근 연구는 ENZC의 특허받은 수축 형태의 페프신 치료법이 유방암, 대장암, 전립선암, 후두암 및 소세포 폐암 등 다양한 암의 성장 및 전파를 감소시키는 데 효과적이라는 결론을 내렸습니다.
Enzolytics, Inc. (OTC PINK:ENZC) a conclu un accord de trois ans avec le Département d'Immunologie, Institut de Microbiologie, Académie Bulgare des Sciences. Cette collaboration vise à accélérer la découverte d'applications combinées et la commercialisation de leurs technologies, en mettant d'abord l'accent sur la combinaison de vecteurs monoclonaux et de protéines immunothérapeutiques (ITP) pour le traitement des antigènes malins.
L'accord implique la réalisation de futures investigations, y compris des études pharmacocinétiques, précliniques et cliniques. Ce partenariat tire parti de l'expertise de l'Institut de Microbiologie Stephan Angeloff (SAIM), qui compte un personnel scientifique de 82 personnes et plus de 30 projets de recherche en cours financés par diverses institutions internationales.
De plus, une étude récente réalisée au Centre National de Maladies Infectieuses et Parasitaires du Ministère de la Santé à Sofia, Bulgarie, a conclu que le traitement expérimental par pepsine lyophilisée brevetée d'ENZC est efficace pour réduire la croissance et la propagation de divers types de cancer, notamment le cancer du sein, du côlon, de la prostate, du larynx et le cancer du poumon à petites cellules.
Enzolytics, Inc. (OTC PINK:ENZC) hat eine dreijährige Vereinbarung mit dem Department of Immunology, Institute of Microbiology, Bulgarische Akademie der Wissenschaften unterzeichnet. Die Zusammenarbeit zielt darauf ab, die Entdeckung von Kombinationsanwendungen und die Vermarktung ihrer Technologien zu beschleunigen, wobei der Fokus zunächst auf der Kombination von monoklonalen Antikörpern und immuntherapeutischen Proteinen (ITP) zur Behandlung von malignen Antigenen liegt.
Die Vereinbarung umfasst die Durchführung zukünftiger Untersuchungen, einschließlich Pharmakokinetik, präklinischen und klinischen Studien. Diese Partnerschaft nutzt die Expertise des Stephan Angeloff Institute of Microbiology (SAIM), das über ein wissenschaftliches Personal von 82 und mehr als 30 laufende Forschungsprojekte verfügt, die von verschiedenen internationalen Institutionen finanziert werden.
Darüber hinaus hat eine aktuelle Studie, die im Nationalen Zentrum für Infektions- und Parasitenkrankheiten des Ministeriums für Gesundheit in Sofia, Bulgarien, durchgeführt wurde, ergeben, dass die patentierte experimentelle Krebsbehandlung mit gefriergetrocknetem Pepsin von ENZC effektiv das Wachstum und die Ausbreitung verschiedener Krebsarten, einschließlich Brust-, Dickdarm-, Prostata-, Kehlkopf- und kleinzelligem Lungenkrebs, verringert.
- Three-year agreement with prestigious Bulgarian research institution to accelerate technology commercialization
- Initial focus on combining Monoclonal Antibodies and Immune Therapeutic Proteins for cancer treatment
- Access to extensive scientific expertise and research capabilities of SAIM
- Positive results from study on ENZC's patented cancer treatment showing effectiveness against multiple cancer types
- No immediate revenue generation from the research agreement
- Uncertain timeline for potential product development and commercialization
- Potential regulatory hurdles and clinical trial risks in drug development process
ALLEN, TX / ACCESSWIRE / September 9, 2024 / Enzolytics, Inc. (OTC PINK:ENZC) ("enzolytics.com") (the "Company") announced today that the Company and the Stephan Angeloff Institute of Microbiology, Department of Immunology, Institute of Microbiology, Bulgarian Academy of Sciences, represented by Professor Tchorbanov PhD, Head of the Department of Immunology and Penka Petrova PHD, DSc, Director of the Institute of Microbiology, entered into a three year agreement to combine their efforts to accelerate discovery of combined applications and commercialization of their individual entity technologies. The initial focus will be combining Monoclonal Antibodies and Immune Therapeutic Proteins ("ITP") for the development of treatments of malignant antigens. Both companies will work together to conduct future investigations such as pharmacokinetics, pre-clinical and clinical trials.
The Stephan Angeloff Institute of Microbiology (SAIM) is comprised of a scientific staff of 82 scientists, including 6 professors, 1 academician (Regular member of BAS), 2 corresponding members of Bulgarian Accreditation Service (BAS), 30 associate professors, 61 PhDs, and 7 DSc. The research work of the Institute consists of research projects funded by foreign and Bulgarian grants. Presently, a total of over 30 projects are funded by foreign institutions (FP7 of the EC, Horizon 2020, NATO grants, UNESCO, Institut Pasteur, EEA Norway Grants, the Swiss Government, and by companies abroad), and by the National Science Research Fund at the Ministry of Education and Science, Bulgaria.
The Department of Immunology within the SAIM is a highly recognized unit performing basic and applied ground-breaking research in immunology. It consists of 3 separate sub-units based on topic and scientific expertise: Laboratory of Infectious Immunology and Inflammation, Laboratory of Experimental Immunotherapy, and Laboratory of Experimental Immunology.
The Department of Immunology occupies five well-equipped laboratories providing an excellent environment for research based on experimental animal models of diseases (barrier-type SPF animal facility), cell culturing (cell culture room with HEPA clean air filter system and collection of cell lines), flow cytometry, histology and immunohistochemistry, cell signaling and protein purification. The Department of Immunology is included in the Bulgarian National Roadmap for Research Infrastructures (NRRI) and has an official accreditation issued by the National Evaluation and Accreditation Agency to train PhD students. (Sources http://micro.bas.bg and http://labexpimm.eu)
The Company recently reported on a study conducted at the Ministry of Health National Centre of Infectious and Parasitic Diseases in Sofia, Bulgaria concluding that Chief Science Officer of ENZC and inventor Harry Zhabilov's, patented experimental cancer lyophilized pepsin treatment, exclusively licensed to Enzolytics, is effective in decreasing the growth and spread of cancer cells in breast cancer, colon cancer, prostate cancer, cancer of the larynx, as well as small cell lung cancer. The report prepared by Prof. Genova-Kalu and Prof. Dr. Iva Hristova concludes with the statement that "In conclusion, lyophilized pepsin has extremely promising biomedical potential."
The National Center of Infectious and Parasitic Diseases (NCIPD) is a national institution with the status of scientific organization under the Ministry of Health. Its aim is to develop the scientific foundations of the fight against infectious diseases and methods for its implementation. This determines the intensive research on etiopathogenesis, immune reactivity, epidemiological features, laboratory diagnostics, treatment and immunoprophylaxis of bacterial and viral, including nosocomial, and parasitic infections.
In 2007 NCIPD was designated by the European Center for Disease Control (ECDC) in Stockholm as the leading, competent national organization, "National competent body" in the field of infectious and parasitic diseases.
NCIPD is the only non-university institution in the country that has been accredited since 1999 by the National Evaluation and Accreditation Agency (NEAA) at the Council of Ministers of the Republic of Bulgaria, as a university in the field of infectology with the rights to train PhD students and conduct postgraduate training in epidemiology, microbiology, virology, parasitology, and immunology and allergies. It has a long tradition of annually organizing dozens of training courses for specialists from the country and abroad with several hundred participants.
The NCIPD hosts all National Reference Laboratories (NRLs) for various bacterial, viral, and parasitic infections. Laboratory Test Complex (LTC), which is for now the only in Bulgaria accredited by the Bulgarian Accreditation Service (BAS) in 2003 under the European requirements of standard BS EN ISO 17025 for quality of work. NRLs are under permanent international external laboratory control of the German accreditation system Instand.
Since 1998 the NCIPD, through the National Reference Laboratories, is conducting a National External Laboratory Control for the Quality of Laboratory Diagnostics carried out by all Microbiological, Virological and Parasitological Laboratories in the country, which, upon successful outcome, allows them to conclude contracts with the National Health Insurance Fund. (source - http://ncipd.org)
Harry Zhabilov, Chief Science Officer of ENZC and source of this opportunity stated, "having the support and acknowledgement of these two prestigious organizations on the unique qualities of the lyophilized pepsin ability to decrease the growth and spread of multiple types of cancer changes the playing field for the New Enzolytics."
Steve Sharabura, the CEO of Enzolytics commented, "This is truly a "Black Swan Opportunity"for those investors who understand the value of this remarkable invention and are willing to see it through to permitting."
About Enzolytics, Inc.
Enzolytics, Inc. is transitioning from solely a drug development company committed to commercializing its proprietary proteins and monoclonal antibodies to treat debilitating infectious diseases to include the additional contracted service areas of sales, marketing and distribution focusing on medical devices, medical testing and nutraceutical products.
Forward Looking Statements
The disclosure herein includes certain statements that are not historical facts but are forward-looking statements for purposes of the safe harbor provisions under the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements generally are accompanied by words such as "believe," "may," "will," "estimate," "continue," "anticipate," "intend," "expect," "should," "would," "plan," "predict," "potential," "seem," "seek," "future," "outlook," and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding projections, estimates and forecasts of revenue and other financial and performance metrics and projections of market opportunity and expectations, Company's ability to enter into a definitive business combination agreement and Company's ability to obtain the financing necessary to consummate the potential business combination transaction. These statements are based on various assumptions and on the current expectations of Company's management and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on by any investor as, a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. Many actual events and circumstances are beyond the control of Company. These forward-looking statements are subject to a number of risks and uncertainties, including: Company's ability to enter into a definitive agreement with respect to the proposed business combination or consummate a transaction; the risk that the approval of the stockholders of Company for the potential transaction is not obtained; failure to realize the anticipated benefits of the potential transaction, including as a result of a delay in consummating the potential transaction or difficulty in integrating the businesses of Company; the amount of redemption requests made by Company's stockholders and the amount of funds remaining in Company's trust account after satisfaction of such requests; those factors discussed in Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2023 under the heading "Risk Factors," and other documents of Company filed, or to be filed, with the SEC. If the risks materialize or assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. There may be additional risks that Company presently does not know or that Company currently believes are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. In addition, forward-looking statements reflect Company's expectations, plans or forecasts of future events and views as of the date hereof. Company anticipates that subsequent events and developments will cause Company's assessments to change. However, while Company may elect to update these forward-looking statements at some point in the future, Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Company's assessments as of any date subsequent to the date of this disclosure statement. Accordingly, undue reliance should not be placed upon the forward-looking statements.
CONTACT INFORMATION:
Enzolytics, Inc.
Steve Sharabura, Chief Executive Officer
1101 Raintree Circle, Suite 130
Allen, Texas 75013
Tel: (845) 925-4597
X/Twitter: @EnzolyticsInc
SOURCE: Enzolytics, Inc.
View the original press release on accesswire.com
FAQ
What is the focus of Enzolytics' (ENZC) new research agreement?
How long is Enzolytics' (ENZC) research agreement with the Bulgarian Academy of Sciences?
What recent study results were reported for Enzolytics' (ENZC) cancer treatment?
Who are the key partners in Enzolytics' (ENZC) new research agreement?
